The JDRF-Lilly project will support cutting-edge research on biomarkers for pancreatic beta cell mass and function, which could indicate the presence of type 1 diabetes. Biomarkers would be a powerful research tool in indicating disease progression and predicting patient responses to treatments.
Researchers at UMass Medical School will study the role of heat shock proteins in type 1 diabetes using dual grants from JDRF and the Iacocca Foundation. The $300,000 funding supports innovative studies across various departments and disciplines to understand Hsp abnormalities that may lead to type 1 diabetes.
JDRF is partnering with Osiris Therapeutics to support a Phase II clinical trial using Prochymal, an immunomodulatory cell therapy product, to preserve and regenerate insulin-producing cells in patients newly diagnosed with type 1 diabetes. The proposed research presents a novel approach for developing a immunomodulatory cellular therapy.
EpiVax receives $351,000 from JDRF to develop Epi-13, a novel therapeutic that reduces harmful immune responses and preserves insulin production. The approach uses natural regulatory T cells to induce antigen-specific adaptive tolerance induction.
The Juvenile Diabetes Research Foundation (JDRF) has partnered with Housey Pharmaceutical Research Laboratories to develop small molecule compounds promoting beta cell growth and survival. This research aims to identify new therapeutics targeting key scientific pathways, accelerating drug discovery and development.
The Juvenile Diabetes Research Foundation announced the 2007 Scholar Award recipients, providing $250,000 annually for up to five years to support groundbreaking research. The selected researchers aim to accelerate type 1 diabetes research and find a cure for this devastating disease.
A Phase 2 clinical trial for ranibizumab is enrolling patients with diabetic macular edema to assess its long-term safety and effectiveness. The trial aims to investigate the use of ranibizumab in combination with laser photocoagulation for treating DME.
Researchers have identified a group of proteins that may play critical roles in causing blood vessel leakage in the eyes of people with diabetic retinopathy. CA-1, an enzyme normally found in red blood cells, was found to increase blood vessel leakage and swelling in both the eyes and brain.
JDRF is providing up to $2 million in funding for the 'Protégé' trial of teplizumab, a proprietary MacroGenics compound that has shown promise in slowing type 1 diabetes progression. The trial aims to assess teplizumab's capacity to reduce insulin requirements and maintain normal blood sugar levels.